2022
Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort
Lu Y, Van Zandt M, Liu Y, Li J, Wang X, Chen Y, Chen Z, Cho J, Dorajoo SR, Feng M, Hsu MH, Hsu JC, Iqbal U, Jonnagaddala J, Li YC, Liaw ST, Lim HS, Ngiam KY, Nguyen PA, Park RW, Pratt N, Reich C, Rhee SY, Sathappan SMK, Shin SJ, Tan HX, You SC, Zhang X, Krumholz HM, Suchard MA, Xu H. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Network Open 2022, 5: e223877. PMID: 35323951, PMCID: PMC8948532, DOI: 10.1001/jamanetworkopen.2022.3877.Peer-Reviewed Original ResearchConceptsDual combination therapyUse of ACEIAntihypertensive drug classesProportion of patientsKhoo Teck Puat HospitalCombination therapyUniversity Hospital databaseHospital databaseDrug classesDual combinationSouth Western Sydney Local Health DistrictWestern Sydney Local Health DistrictPatients age 65 yearsSydney Local Health DistrictElectronic health record databasePatients age 18Local Health DistrictAge 65 yearsTreatment of hypertensionHealth record databaseARB monotherapyTreatment escalationAdult patientsCohort studyCombination regimen
2021
Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States
Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham H, Zhou Y, Li J, Zhang X, Xu H, Taner C, Yang L, Tao C. Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Alimentary Pharmacology & Therapeutics 2021, 54: 481-492. PMID: 34224163, DOI: 10.1111/apt.16490.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsCarcinoma, HepatocellularHumansLiver CirrhosisLiver NeoplasmsRetrospective StudiesUnited StatesConceptsRisk of HCCBeta-blocker groupHepatocellular carcinomaCirrhotic patientsCerner Health Facts databaseCox proportional hazards regressionCumulative HCC incidenceRetrospective cohort studyHealth Facts databasePopulation-based studyProportional hazards regressionKaplan-Meier estimatesEligible patientsCohort studyHCC incidenceFinal cohortHazards regressionHCC riskLower riskPropensity scorePatientsCarvedilolRiskFacts databaseGroup